nach oben

Medical Oncology

Erschienen in:

01.01.2014 | Original Paper

Reduced expression of Slit2 in renal cell carcinoma

verfasst von: Wei-Jie Ma, Yu Zhou, Dan Lu, Dong Dong, Xiao-Jun Tian, Jie-xi Wen, Jun Zhang

Erschienen in: Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Slit2, initially identified as an important axon guidance molecule in the nervous system, was suggested to be involved in multiple cellular processes. Recently, Slit2 was reported to function as a potential tumor suppressor in diverse tumors. In this study, we systematically analyzed the expression level of Slit2 in renal cell carcinoma. Compared to paired adjacent non-malignant tissues, both Slit2 mRNA and protein expression were significantly down-regulated in renal cell carcinoma (RCC). Methylation-specific PCR showed that Slit2 promoter was methylated in two renal carcinoma cell lines. Pharmacologic demethylation dramatically induced Slit2 expression in cancer cell lines with weak expression of Slit2. Besides, bisulfite genomic sequencing confirmed that dense methylation existed in Slit2 promoter. Furthermore, in paired RCC samples, Slit2 methylation was observed in 8 out of 38 patients (21.1 %), which was well correlated with the down-regulation of Slit2 in RCC. Therefore, Slit2 may also be a potential tumor suppressor in RCC, which is down-regulated in RCC partially due to promoter methylation.

de Ibanez Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res. 2006;66(10):5021–8. doi:10.1158/0008-5472.CAN-05-3365.CrossRef

Onay H, Onay H, Pehlivan S, Koyuncuoglu M, Kirkali Z, Ozkinay F. Multigene methylation analysis of conventional renal cell carcinoma. Urol Int. 2009;83(1):107–12. doi:10.1159/000224878.PubMedCrossRef

Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85–90. doi:10.1038/ng0594-85.PubMedCrossRef

Kikuyama M, Takeshima H, Kinoshita T, Okochi-Takada E, Wakabayashi M, Wakabayashi M, Akashi-Tanaka S, Akashi-Tanaka S, et al. Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation. Cancer Lett. 2012;322(2):204–12. doi:10.1016/j.canlet.2012.03.016.PubMedCrossRef

Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta. 2008;1785(2):133–55. doi:10.1016/j.bbcan.2007.12.002.PubMed

Morris MR, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, et al. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer. 2008;98(2):496–501. doi:10.1038/sj.bjc.6604180.PubMedCentralPubMedCrossRef

Hoffman AM, Cairns P. Epigenetics of kidney cancer and bladder cancer. Epigenomics. 2011;3(1):19–34. doi:10.2217/epi.10.64.PubMedCentralPubMedCrossRef

Morris, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010;29(14):2104–17. doi:10.1038/onc.2009.493.PubMedCentralPubMedCrossRef

Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, et al. Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int J Oncol. 2008;32(6):1253–61.PubMed

10.

Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, et al. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol. 2008;180(1):343–51. doi:10.1016/j.juro.2008.02.044.PubMedCrossRef

11.

Lv D, Zhao W, Dong D, Qian XP, Zhang Y, Tian XJ, et al. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma. Eur J Cancer. 2011;47(13):2068–76. doi:10.1016/j.ejca.2011.04.021.PubMedCrossRef

12.

Lu D, Dong D, Zhou Y, Lu M, Pang XW, Li Y, et al. The tumor-suppressive function of UNC5D and its repressed expression in renal cell carcinoma. Clin Cancer Res. 2013;19(11):2883–92. doi:10.1158/1078-0432.CCR-12-2978.PubMedCrossRef

13.

Kidd T, Bland KS, Goodman CS. Slit is the midline repellent for the robo receptor in Drosophila. Cell. 1999;96(6):785–94.PubMedCrossRef

14.

Brose K, Bland KS, Wang KH, Arnott D, Henzel W, Goodman CS, et al. Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell. 1999;96(6):795–806.PubMedCrossRef

15.

Legg JA, Herbert JM, Clissold P, Bicknell R. Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008;11(1):13–21. doi:10.1007/s10456-008-9100-x.PubMedCrossRef

16.

Singh RK, Indra D, Mitra S, Mondal RK, Basu PS, Roy A, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet. 2007;122(1):71–81. doi:10.1007/s00439-007-0375-6.PubMedCrossRef

17.

Narayan G, Goparaju C, Arias-Pulido H, Kaufmann AM, Schneider A, Durst M, et al. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer. 2006;5:16. doi:10.1186/1476-4598-5-16.PubMedCentralPubMedCrossRef

18.

Alvarez C, Tapia T, Cornejo V, Fernandez W, Munoz A, Camus M, et al. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer. Mol Carcinog. 2013;52(6):475–87. doi:10.1002/mc.21881.PubMedCrossRef

19.

Dallol A, Krex D, Hesson L, Eng C, Maher ER, Latif F. Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene. 2003;22(29):4611–6. doi:10.1038/sj.onc.1206687.PubMedCrossRef

20.

Dallol A, Morton D, Maher ER, Latif F. SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res. 2003;63(5):1054–8.PubMed

21.

Qiu H, Zhu J, Yu J, Pu H, Dong R. SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated. Asian Pac J Cancer Prev APJCP. 2011;12(3):791–5.

22.

Dunwell TL, Dickinson RE, Stankovic T, Dallol A, Weston V, Austen B, et al. Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia. Epigenetics. 2009;4(4):265–9.PubMed

23.

Kolodkin AL, Tessier-Lavigne M. Mechanisms and molecules of neuronal wiring: a primer. Cold Spring Harbor perspectives in biology. 2011;3(6). doi:10.1101/cshperspect.a001727.

24.

Mertsch S, Schmitz N, Jeibmann A, Geng JG, Paulus W, Senner V. Slit2 involvement in glioma cell migration is mediated by Robo1 receptor. J Neurooncol. 2008;87(1):1–7. doi:10.1007/s11060-007-9484-2.PubMedCrossRef

25.

Fitamant J, Guenebeaud C, Coissieux MM, Guix C, Treilleux I, Scoazec JY, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA. 2008;105(12):4850–5. doi:10.1073/pnas.0709810105.PubMedCrossRef

26.

Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol. 2009;11(11):1325–31. doi:10.1038/ncb1976.PubMedCentralPubMedCrossRef

27.

Wang B, Xiao Y, Ding BB, Zhang N, Yuan X, Gui L, et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell. 2003;4(1):19–29.PubMedCrossRef

28.

Astuti D, Da Silva NF, Dallol A, Gentle D, Martinsson T, Kogner P, et al. SLIT2 promoter methylation analysis in neuroblastoma, Wilms’ tumour and renal cell carcinoma. Br J Cancer. 2004;90(2):515–21. doi:10.1038/sj.bjc.6601447.PubMedCentralPubMedCrossRef

29.

Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, et al. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res. 2002;62(20):5874–80.PubMed

Titel: Reduced expression of Slit2 in renal cell carcinoma
verfasst von: Wei-Jie Ma
Yu Zhou
Dan Lu
Dong Dong
Xiao-Jun Tian
Jie-xi Wen
Jun Zhang
Publikationsdatum: 01.01.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 1/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-013-0768-4

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Reduced expression of Slit2 in renal cell carcinoma

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of China

Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis

Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma

Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases

Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer

Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie